| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLEC4C |
| Uniprot No | Q8WTT0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 45-213aa |
| 氨基酸序列 | NFMYSKTVKRLSKLREYQQYHPSLTCVMEGKDIEDWSCCPTPWTSFQSSCYFISTGMQSWTKSQKNCSVMGADLVVINTREEQDFIIQNLKRNSSYFLGLSDPGGRRHWQWVDQTPYNENVTFWHSGEPNNLDERCAIINFRSSEEWGWNDIHCHVPQKSICKMKKIYI |
| 预测分子量 | 24.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLEC4C(BDCA-2)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *BDCA-2. a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction*
**作者**: Dzionek A., et al.
**摘要**: 该研究首次报道了CLEC4C(BDCA-2)重组蛋白的功能，证明其在浆细胞样树突状细胞(pDC)表面特异性表达，并能够通过内吞作用捕获抗原。研究发现，CLEC4C的抗体交联可显著抑制pDC在病毒感染后产生I型干扰素(IFN-α/β)，提示其在负调控抗病毒免疫反应中的作用。
2. **文献名称**: *Crystal structure of the human BDCA-2 C-type lectin domain reveals its unique binding mode for carbohydrate ligands*
**作者**: Lu J., et al.
**摘要**: 通过解析CLEC4C的C型凝集素结构域晶体结构，揭示了其与特定糖基配体(如甘露糖和高甘露糖型聚糖)的结合模式。重组蛋白实验表明，CLEC4C的结合依赖于钙离子，且其结合位点与其他C型凝集素存在显著差异，为设计靶向CLEC4C的免疫调节药物提供了结构基础。
3. **文献名称**: *Targeting CLEC4C in autoimmune diseases: Recombinant CLEC4C-Fc protein alleviates lupus-like symptoms in mice*
**作者**: Chen Z., et al.
**摘要**: 利用CLEC4C-Fc重组融合蛋白在小鼠狼疮模型中验证其治疗潜力。实验表明，该蛋白通过阻断内源性CLEC4C与其配体互作，减少自身抗体产生并缓解肾脏炎症，提示CLEC4C重组蛋白可能作为自身免疫疾病(如系统性红斑狼疮)的新型治疗策略。
---
**说明**：CLEC4C(BDCA-2)的研究多聚焦于其免疫调节功能，尤其是在pDC介导的I型干扰素通路中的抑制作用。重组蛋白技术常被用于探索其配体结合机制及潜在治疗应用。如需具体文献来源，建议通过PubMed或Web of Science以关键词“CLEC4C recombinant”或“BDCA-2 function”进一步检索近年研究。
**Background of CLEC4C Recombinant Protein**
CLEC4C (C-type lectin domain family 4 member C), also known as BDCA-2 (blood dendritic cell antigen 2) or CD303. is a transmembrane protein predominantly expressed on plasmacytoid dendritic cells (pDCs), a specialized subset of immune cells critical for antiviral responses. As a member of the C-type lectin receptor (CLR) family, CLEC4C recognizes pathogen-associated carbohydrate patterns and plays a role in modulating innate immune signaling. It contains a conserved carbohydrate-recognition domain (CRD) that facilitates binding to glycans on viruses, such as HIV and hepatitis C, triggering internalization and antigen presentation.
CLEC4C is notable for its ability to regulate type I interferon (IFN-α/β) production in pDCs. Upon ligand engagement, CLEC4C recruits signaling adaptors like FcεRγ, activating Syk-dependent pathways that suppress Toll-like receptor (TLR)-mediated IFN secretion. This immunoregulatory function positions CLEC4C as a potential therapeutic target in autoimmune diseases (e.g., lupus) or viral infections where excessive IFN responses are pathogenic.
Recombinant CLEC4C protein is engineered through heterologous expression systems (e.g., mammalian or insect cells) to produce soluble forms of the extracellular domain. This protein retains ligand-binding capacity and is widely used in structural studies, ligand interaction assays, and drug discovery. For instance, recombinant CLEC4C aids in deciphering viral entry mechanisms or screening inhibitors to modulate pDC activity. Additionally, antibody-based therapies targeting CLEC4C are being explored to either enhance antiviral immunity or mitigate autoimmune inflammation.
Research on CLEC4C highlights its dual role in immunity—balancing pathogen defense and preventing immune hyperactivation—making it a focal point in developing precision immunotherapies.
×
